Clinical Cancer Research, Vol 4, Issue 3 595-604, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks

SG Eckhardt, SD Baker, JR Eckardt, TG Burke, DL Warner, JG Kuhn, G Rodriguez, S Fields, A Thurman, L Smith, ML Rothenberg, L White, P Wissel, R Kunka, S DePee, D Littlefield, HA Burris, DD Von Hoff and EK Rowinsky
Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA.

GI1147211 is a 7-substituted 10,11-ethylenedioxy-20(S)-camptothecin analogue that inhibits the nuclear enzyme topoisomerase I. In this Phase I and pharmacological study, 24 patients with advanced solid malignancies received a total of 72 courses of GI147211 as a 30-min infusion daily for 5 consecutive days, at doses ranging from 0.3 to 1.75 mg/m2/day. Severe neutropenia precluded dose escalation above 1.5 mg/m2/day in minimally pretreated patients, and both severe neutropenia and thrombocytopenia were dose limiting in heavily pretreated patients at doses above 1.0 mg/m2/day. These doses are, therefore, recommended for subsequent Phase II evaluations of GI147211 in patients with comparable prior therapy. Nonhematological toxicities, including nausea, vomiting, fatigue, and anorexia, were mild to moderate. The disposition of GI147211 in blood was described by a linear three-compartment model, with renal elimination accounting for only 11% of drug distribution. No relationship was observed between the pharmacological exposure to GI147211 and effects on neutrophils; however, patients who developed dose-limiting myelosuppression did experience greater exposure to both the lactone and total forms of the drug. The hydrolysis kinetics of GI147211 revealed not only a shift of the drug to the inactive carboxylate form in human serum albumin but also stabilization of the lactone in erythrocytes, perhaps accounting for the observed lactone:total area under the concentration-time curve ratio of 0.27. These results indicate that GI147211 exhibits predictable toxicities and that further studies are warranted to determine the distinct role of this compound among currently available camptothecin analogues.

This article has been cited by other articles:

				D. F.S. Kehrer, A. M. Bos, J. Verweij, H. J. Groen, W. J. Loos, A. Sparreboom, M. J.A. de Jonge, M. Hamilton, T. Cameron, and E. G.E. de Vries Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity J. Clin. Oncol., March 1, 2002; 20(5): 1222 - 1231. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				W. J. Loos, J. Verweij, D. F. S. Kehrer, P. de Bruijn, F. M. H. de Groot, M. Hamilton, K. Nooter, G. Stoter, and A. Sparreboom Structural Identification and Biological Activity of 7-Methyl-10,11-Ethylenedioxy-20(S)-Camptothecin, a Photodegradant of Lurtotecan Clin. Cancer Res., March 1, 2002; 8(3): 856 - 862. [Abstract] [Full Text] [PDF]

				C. F. VERSCHRAEGEN, K. JAECKLE, B. GIOVANELLA, V. KNIGHT, and B. E. GILBERT Alternative Administration of Camptothecin Analogues Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 237 - 246. [Abstract] [Full Text] [PDF]

				D. L. Emerson, R. Bendele, E. Brown, S. Chiang, J. P. Desjardins, L. C. Dihel, S. C. Gill, M. Hamilton, J. D. LeRay, L. Moon-McDermott, et al. Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan Clin. Cancer Res., July 1, 2000; 6(7): 2903 - 2912. [Abstract] [Full Text]